Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-defensin 105B (DEFB105B) is a small, cationic antimicrobial peptide belonging to the beta-defensin family, which is widely implicated in the innate immune defense of epithelial surfaces against pathogens[1][6][7]. Like other beta-defensins, it is characterized by a structure containing six conserved cysteine residues forming three intramolecular disulfide bonds, giving the peptide a stable β-sheet conformation and amphipathic properties essential for disrupting microbial membranes[2][5]. Beta-defensin 105B exerts broad-spectrum antimicrobial activity, disrupting the membrane integrity of bacteria (both Gram-negative and Gram-positive), fungi, and some enveloped viruses[2][4][7]. The gene encoding Beta-defensin 105B is located on human chromosome 8p23, typically in a duplicated cluster alongside DEFB105A, with both genes producing nearly identical peptides expressed in epithelial tissues[1][6]. Beyond direct microbicidal effects, beta-defensins are recognized for immunomodulatory functions, including the recruitment and activation of immune cells such as dendritic cells, T lymphocytes, and mast cells via chemotactic activity[4][7]. While no drugs currently target this molecule directly, and it is not a classic pharmacological receptor or enzyme, its roles in immune defense and disease make it a protein of interest for infectious and inflammatory disease research[1][4][7]. **Note:** - There is no evidence in current major databases or literature that Beta-defensin 105B (DEFB105B) is misspelled, conceptually incorrect, or an invalid target.[1][6] - No specific drugs are known to target DEFB105B or use it as a biomarker; its therapeutic targeting is primarily theoretical at this time. - Its classification as a “target” is based on its established and broad roles as a direct effector in innate immunity, not as a receptor, enzyme, transporter, or classic drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-defensin 105B (DEFB105B).